Skip to NavigationSkip to content

Executive shake-up at Novartis after Zolgensma data scandal

Published on 14/08/19 at 05:21pm

The AveXis executives that oversaw the marketing application for Zolgensma, the $2.1 million gene therapy at the centre of the faulty data scandal, are “no longer with the company” and “have not been involved” in any operations since early May, AveXis said.

Brothers Dr Brian Kaspar, Chief Scientific Officer at AveXis and Dr Allan Kaspar, Senior Vice President Research and Development at AveXis have been replaced by Dr Page Bouchard who will take over both their roles.

Novartis veteran Dr Bouchard, who has spent ten years at the firm and has overseen the development of over 100 investigational drug programmes and dozens of new drug applications and biologics license applications, has been parachuted in to take over the Kaspar brother’s roles.

The revelations come after Senator Chuck Grassley called on Novartis to reveal the details of the data scandal, including information on how many Novartis employees had been terminated for manipulating Zolgensma data.

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches